Skip to content

CRIO Welcomes Dr. Margaretta Nyilas to its Board of Directors

 BOSTON, MA – November 3, 2022CRIO, the industry’s leading eSource provider, announces the appointment of Dr. Margaretta Nyilas to its Board of Directors, effective immediately. 

Dr. Nyilas is a biopharmaceutical executive with over twenty years of diverse global industry experience, formerly at Otsuka Pharmaceuticals, Bristol Myers Squibb and Click Therapeutics. She has a proven track record of delivering high value assets such as ABILIFY MYCITE® (aripiprazole tablets with sensors), ABILIFY MAINTENA® (aripiprazole),  REXULTI™ (brexpiprazole), and ABILIFY® (aripiprazole). 

Currently, she is serving as a director and strategic advisor for the biopharmaceutical industry and as Venture Affiliate Partner with Boston Millennia Partners. 

Throughout her career, Dr. Nyilas has championed innovation in the clinical trial process and was an early adopter of electronic source data collection. She joins CRIO as its first independent director, bringing her unique blend of knowledge in clinical operations, technology and medicine.

“We couldn’t be happier with Margaretta joining the Board,” says Raymond Nomizu, JD, CEO and co-founder at CRIO. “With over 2,000 sites using our system across thousands of studies, we are leveraging our technology to create efficiencies for sites, sponsors and CROs. As an innovator in eClinical technology, Margaretta will provide invaluable insight and guidance to position our product roadmap and vision to the needs of clinical trial sponsors.”

Dr. Nyilas joins CRIO board members Sankesh Abbhi, formerly CEO of ArisGlobal; Tom Peterson, Venture Partner at Rally Ventures; and CEO, Raymond Nomizu. Ren Roome of Boston Millennia Partners serves as a board observer.

About CRIO

CRIO is an eClinical solution provider delivering innovative data capture technology for sites, sponsors and CROs. Innovation is at the heart of everything we do. As the industry’s leading eSource provider, CRIO’s unique architecture enables a single point of data capture that embeds quality and transparency at the point of entry, and creates significant downstream efficiencies. Finally. One system. One source. Today, CRIO supports more than 2,000 medical research sites and 4,000+ protocols worldwide. For more information about CRIO, visit


by Daenya McDonald Marketing Director
Share this post
You may also find interesting
Explore our Blog
CRIO bugathon CRIO Company News

CRIO Bugathon – Building the Ultimate Platform

While bugs are as natural in coding as they are in nature, we don’t want them creeping into our code. At CRIO, we have established various processes and procedures to handle bugs. At the close of 2022, we hosted a Bugathon, part of our ongoing efforts to deliver best-in-class quality. The Bugathon was a two...

3 Reasons to visit CRIO at SCRS 2022 CRIO Company News

3 Reasons to Visit CRIO at SCRS 2022

SCRS 2022 starts next week. Here are 3 reasons to stop by Booth 401 and meet Team CRIO. We’ll see you there!  Friday, Oct.7 at 10:30 am. Master Workshop #1 : How the World’s Leading Vaccine Network Reduced Protocol Deviations by 40% 2. Meet the team behind the industry’s leading site-based eSource technology. CRIO delivers...

CRIO Company News

CRIO Selected for Fully Virtual Decentralized Clinical Trial

CRIO and strategic partner Jiva Science are providing eSource, Telehealth, eConsent and ePRO in support of a Major Depressive Disorder (MDD) virtual trial BOSTON, Aug. 23, 2022 – CRIO, a Boston-based healthcare technology firm streamlining clinical trials for sponsors, sites, and patients, has been selected as the eSource vendor for a 200 patient MDD trial. The study...